Date Published: February 28, 2019
Publisher: Impact Journals
Author(s): Juan Wang, Sayyed Hanif Ullah, Meihe Li, Miao Zhang, Fujun Zhang, Jin Zheng, Xiaofei Yan.
Reduced Na+-K+-ATPase function is reported in various renal diseases. This implies that increase of Na+-K+-ATPase function may be a new target in treatment of renal injury. We previously reported that Na+-K+-ATPase was stabilized by DRm217, a specific antibody against DR region of Na+-K+-ATPase. In this study, we compared the protective effect of DRm217 and ouabain on kidney in a chronic kidney disease rat model and investigated the mechanism under it. We found that DRm217 improved renal function, alleviated glomerulus atrophy, inhibited renal tubular cells apoptosis, tubulointerstitial injury and renal fibrosis in 5/6 nephrectomized rats. Contrary to DRm217, ouabain worsened renal damage. Activated Na+-K+-ATPase /Src signaling pathway, increased oxidant stress and activated inflammasome were responsible for nephrectomized or ouabain-induced renal injury. DRm217 inhibited Na+-K+-ATPase /Src signaling pathway, retarded oxidant stress, suppressed inflammasome activation, and improved renal function, suggesting a novel approach to prevent renal damage.
Chronic kidney disease (CKD) is a progressive disease which leads to gradual loss of kidney function in all age groups . The precise prevalence of CKD is still not known. But it is estimated that there are approximately 7% young adults and 35% elders suffer from CKD . It leads to progressive renal failure and cardiovascular system diseases, including heart failure . Though much have been learned about the mechanism of CKD, fewer therapeutic strategies have been shown to improve renal outcome. Accordingly, the development of innovative therapies to prevent renal damage in CKD is very important.
CKD is characterized by an irreversible deterioration of renal function, with glomerular atrophy, glomerular compensatory hypertrophy, nephric tubular degeneration, and renal fibrosis as the final common pathologic change. Identify treatment targets for slowing CKD development is a hot topic in renal research. In the present study, we demonstrated that DRm217, a specific antibody against DR region of Na+-K+-ATPase, restored renal function in 5/6 nephrectomized rats. We showed that DRm217 administration also attenuated glomerulus atrophy, renal tubular cells apoptosis, tubulointerstitial injury and renal fibrosis in the injured kidney. Interestingly, ouabain, a natural and classical ligand of Na+-K+-ATPase, deteriorated renal injury in 5/6 nephrectomized rats. Collectively, these data suggested that Na+-K+-ATPase acts as a key mediator in the process of renal disease.